A new experimental drug was found to "significantly" reduce the progression of brain cancer, Reuters reported.
Vorasidenib, created by Servier Group, a private drug developer, was shown to slow the progression of brain tumors by an average of over 16 months, per Bloomberg. The results of the 331-patient study were published June 4 in The New England Journal of Medicine.
The study's lead author, Ingo Mellinghoff, described this as "a very big finding," adding that the drug "is the first molecularly targeted treatment for diffuse glioma." Vorasidenib specifically works on Grade 2 gliomas, which are "progressive, malignant brain tumors" that are "more common in adults but can also occur in children and teenagers," according to Reuters. The drug blocks a specific enzyme mutated in low-grade gliomas, keeping them from progressing and postponing the need for further treatment like chemotherapy.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
"What you just heard is a trial that was well done and well thought out: to use an oral, targeted, well-tolerated therapy to see if we could delay the use of our standard chemotherapy and radiation," Wake Forest Baptist Health's Dr. Glenn Lesser commented at an American Society of Clinical Oncology briefing. "The results are quite striking and they're statistically highly significant, and more importantly, they're clinically very, very significant."
Servier Group is working to get the drug approved by the Food & Drug Administration for use in the U.S.
-
Film reviews: Springsteen: Deliver Me From Nowhere, If I Had Legs I’d Kick You, Frankenstein, and Blue MoonFeature A rock star on the rise turns inward, a stressed mother begins to unravel, and more
-
Podcast reviews: ‘Fela Kuti: Fear No Man,’ ‘David Bowie: Changeling’ and ‘The Adam Friedland Show’feature Fela Kuti’s revolutionary life, David Bowie’s early years, and Adam Friedland reinvents the talk show
-
What does history say about Trump’s moves in Latin America?Today's Big Question ‘Bitter memories’ surface as US targets Venezuela
-
Peanut allergies have plummeted in childrenUnder the radar Early introduction could be an effective prevention method
-
Climate change is getting under our skinUnder the radar Skin conditions are worsening because of warming temperatures
-
Is this the end of ultraprocessed foods?Today's Big Question California law and the MAHA movement are on the same track
-
Bluetoothing: the phenomenon driving HIV spike in FijiUnder the Radar ‘Blood-swapping’ between drug users fuelling growing health crisis on Pacific island
-
FDA OKs generic abortion pill, riling the rightSpeed Read The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions
-
The new Stratus Covid strain – and why it’s on the riseThe Explainer ‘No evidence’ new variant is more dangerous or that vaccines won’t work against it, say UK health experts
-
‘Nightmare bacteria’ are rapidly spreadingUnder the radar The infections are largely resistant to antibiotics
-
Kissing bug disease has a growing presence in the USThe explainer The disease has yielded a steady stream of cases in the last 10 years
